1,721,416 research outputs found
Extrahepatic Manifestations of Chronic Viral C Hepatitis
No full textHepatits C virus (HCV) infection has been largely associated with extrahepatic comorbidities such as diseases related to dysregulation of the immune system, neuropsychiatric disorders, and cardiometabolic alterations. These clinical consequences, together with experimental evidence, suggest a potential (in)direct effect of HCV, contributing to the pathogenesis of these diseases. Various studies have reported a positive effect of viral eradication on occurrence and outcomes of extrahepatic diseases. These observations and the availability of safe and effective direct antiviral agents further underline the need to search for virological eradication in all infected individuals independent of the severity of the liver disease
Corrigendum to "Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)" [Dig Liver Dis 54 (2022) 170-182]
No full textn
Reply to 'Genetic and clinical data reinforce the role of GAS6 and TAM receptors in liver fibrosis'
No full text
Emerging Increase in the prevalence and severity of nonalcoholic fatty liver disease: epidemiological study from general Mediterranean population
No full textBackground and Aims: The worldwide spread of obesity and
diabetes is leading to a drastic increase in nonalcoholic fatty liver
disease (NAFLD) and its complications.We aimed to assess prevalence
of NAFLD and of its severity among a general Mediterranean
population.
Methods:We considered 886 consecutive individuals included in the
ABCD study (ISRCTN15840340). Hepatic ultrasound (US) was used to
diagnose steatosis and FibroScan (M and XL probe) to measure
liver stiffness and controlled attenuation parameter (CAP). Liver
stiffness >6.9 KPa was considered suggestive of significant liver
fibrosis (Petta S et al., Hepatology 2015), and CAP ≥ 310 dB was
considered suggestive of moderate-severe steatosis (de Ledinghen V
et al., JHEP 2014).
Results: Steatosis by USwas diagnosed in 396 individuals (44.6%) and
was significantly associated with male gender, type 2 diabetes, low
HDL (<40 mg/mL in males and <50 mg/mL in females), and visceral
obesity. When splitting the analysis according to gender, steatosis
was independently linked to visceral obesity (OR 2.63, 95% CI 1.62–
4.27, p < 0.001) and low HDL (OR 2.06, 95% CI 1.10–3.85, p = 0.02) in
males, and to visceral obesity (OR 2.75, 95% CI 1.80–4.19, p < 0.001)
and type 2 diabetes (OR 2.19, 95% CI 1.00–4.87, p = 0.05) in females.
The rate of US steatosis, stiffness >6.9 kPa and CAP ≥310 progressively
increased from males without obesity and low HDL (35.1% steatosis;
among theme 18.6% CAP ≥310, and 13.5% stiffness >6.9), to those with
one risk factor (from 57.7% to 62.1% steatosis; among them 42.8% CAP
≥310, and from 21.4% to 23.2% stiffness >6.9), and further to those
with both risk factors (74.2% steatosis; among them 35% CAP ≥310,
and 30% stiffness >6.9). Similarly, in females the rate of US steatosis,
stiffness >6.9 kPa and CAP ≥310 progressively increased from patients
without obesity and diabetes (23.7% steatosis; among them 6.1% CAP
≥310, and 6.1% stiffness >6.9), to those with only one risk factor (from
33.3% to 50.8% steatosis; among them CAP ≥310 from 30.5% to 54.5%,
and stiffness >6.9 from 11.1% to 27.2%), and further to those with both
risk factors (74.2% steatosis; among them 47.1% CAP ≥ 310, and 26.4%
stiffness >6.9).
Conclusions: NAFLD is present in more than 40% of general
population and its prevalence, as well as the prevalence of live
- …
